Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company. If you are a reporter with a question about Regeneron, please call our Media Line at (914) 847-7800.
For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com .
Jan 26, 2012
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Jan 3, 2012
Regeneron Announces Presentation at the 30th Annual J. P. Morgan Healthcare Conference
Jan 3, 2012
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Jan 2, 2012
Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
Dec 5, 2011
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity
Dec 1, 2011
Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
Nov 28, 2011
Regeneron and Bayer Initiate Phase 3 Clinical Program for the Treatment of Wet Age-Related Macular Degeneration in China
Nov 23, 2011
Regeneron Announces Upcoming Investor Conference Presentations
Nov 22, 2011
Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
Nov 21, 2011
Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds
Regeneron Pharmaceuticals Q4 and Year End Earnings Conference Call
